Lite Strategy (LITS) Capital Expenditures (2010 - 2025)
Lite Strategy (LITS) posted Capital Expenditures of $100.0 million for Q3 2025, up 1428471.43% on a QoQ basis from $7000.0 in Q3 2023.
Analysis
Lite Strategy (LITS) Capital Expenditures (2010 - 2025) Analysis & Trends
Lite Strategy has reported Capital Expenditures for 13 years, with the latest figure at $100.0 million in Q3 2025.
- On a quarterly basis, Capital Expenditures changed N/A year-over-year to $100.0 million in Q3 2025; TTM through Mar 2026 was $100.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $7000.0, down 80.0% from the prior year.
- Capital Expenditures was $100.0 million for Q3 2025 at Lite Strategy, up from $7000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $100.0 million in Q3 2025, with the low at -$63000.0 in Q4 2022.
- Average Capital Expenditures over 4 years is $10.1 million, with a median of $43000.0 recorded in 2021.
- The largest YoY upside for Capital Expenditures was 3725.0% in 2022 against a maximum downside of 223.53% in 2022.
- Over 4 years, Capital Expenditures stood at $51000.0 in 2021, then tumbled by 223.53% to -$63000.0 in 2022, then soared by 111.11% to $7000.0 in 2023, then soared by 1428471.43% to $100.0 million in 2025.
- The last three Capital Expenditures figures came in at $100.0 million (Q3 2025), $7000.0 (Q3 2023), and $35000.0 (Q2 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 100.00 Mn |
| Sep 30, 2023 | 7,000.00 |
| Jun 30, 2023 | 35,000.00 |
| Dec 31, 2022 | -63,000.00 |
| Sep 30, 2022 | 63,000.00 |
| Jun 30, 2022 | 306,000.00 |
| Mar 31, 2022 | 114,000.00 |
| Dec 31, 2021 | 51,000.00 |
| Sep 30, 2021 | 8,000.00 |
| Jun 30, 2021 | 8,000.00 |
| Dec 31, 2020 | 56,000.00 |
| Sep 30, 2020 | 644,000.00 |
| Jun 30, 2020 | 109,000.00 |
| Mar 31, 2020 | 780,000.00 |
| Jun 30, 2019 | 10,000.00 |
| Mar 31, 2019 | 35,000.00 |
| Jun 30, 2017 | 49,000.00 |
| Sep 30, 2016 | 2,000.00 |
| Jun 30, 2016 | 1,000.00 |
| Jun 30, 2015 | -1,000.00 |